問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberC1171002
Completed

2017-09-01 - 2019-01-03

Others

Terminated7

ICD-10K76.0

Fatty (change of) liver, not elsewhere classified

ICD-10K75.81

Nonalcoholic steatohepatitis (NASH)

ICD-9573.8

Other specified disorders of liver

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator Wan-Long Chuang 未分科

Co-Principal Investigator

Audit

None

Principal Investigator Yi-Hsiang Huang Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Jia-Horng Kao Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Wen-Juei Jeng Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Jing-Houng Wang Division of General Internal Medicine

Co-Principal Investigator

  • 歐信佑 Division of General Internal Medicine
  • 紀廣明 Division of General Internal Medicine
  • 張國欽 Division of General Internal Medicine
  • 洪肇宏 Division of General Internal Medicine
  • 盧勝男 Division of General Internal Medicine
  • 沈峰志 Division of General Internal Medicine
  • 顏毅豪 Division of General Internal Medicine
  • 陳建宏 Division of General Internal Medicine

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 顏旭亨 Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Pin-Nan Cheng Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Wan-Long Chuang Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    25 participants

  • Global

    360 participants